Pitcairn Co. Sells 16,491 Shares of DexCom, Inc. (NASDAQ:DXCM)

Pitcairn Co. decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCMFree Report) by 30.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,592 shares of the medical device company’s stock after selling 16,491 shares during the period. Pitcairn Co.’s holdings in DexCom were worth $4,665,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. DSM Capital Partners LLC bought a new position in DexCom in the 4th quarter worth $28,000. Valley National Advisers Inc. boosted its holdings in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares during the period. MV Capital Management Inc. boosted its holdings in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after buying an additional 138 shares during the period. Smithfield Trust Co boosted its holdings in DexCom by 103.1% in the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after buying an additional 165 shares during the period. Finally, Washington Trust Advisors Inc. boosted its holdings in DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after buying an additional 193 shares during the period. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of several recent analyst reports. Raymond James upped their target price on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Royal Bank of Canada initiated coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price for the company. Redburn Atlantic initiated coverage on shares of DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price objective for the company. Canaccord Genuity Group increased their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Finally, UBS Group increased their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $140.94.

Read Our Latest Stock Analysis on DXCM

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 49,633 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $138.30, for a total value of $6,864,243.90. Following the sale, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Kevin R. Sayer sold 49,633 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the transaction, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at $39,262,401.90. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 2,624 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total transaction of $367,464.96. Following the transaction, the executive vice president now directly owns 68,682 shares in the company, valued at $9,618,227.28. The disclosure for this sale can be found here. Insiders have sold 60,837 shares of company stock valued at $8,377,125 in the last ninety days. 0.30% of the stock is owned by company insiders.

DexCom Price Performance

Shares of NASDAQ DXCM traded up $0.21 during mid-day trading on Wednesday, hitting $117.11. 835,121 shares of the company’s stock traded hands, compared to its average volume of 2,901,491. The company’s 50-day moving average is $128.85 and its two-hundred day moving average is $125.95. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The company has a market capitalization of $46.57 billion, a P/E ratio of 75.69, a PEG ratio of 2.85 and a beta of 1.22. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCMGet Free Report) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. On average, equities analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

About DexCom

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Read More

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.